Loading quotes...

Forecast

The analysts' average price target is €128.71 (+61.39%). The median is €137.24 (+72.09%).

Buy	22
Hold	0
Sell	0

News Go to news feed

Rhythm Pharmaceuticals: launch of IMCIVREE for hypothalamic obesity gains momentum

Rhythm Pharmaceuticals said at the Wells Fargo conference that the launch of IMCIVREE for hypothalamic obesity is in the “second quarter” of rollout and that there are already about 400 prescriptions from roughly 300 physicians. The company sees hypothalamic obesity (HO), Bardet‑Biedl syndrome and Prader‑Willi syndrome as strategic growth areas and reported positive Phase II data in Prader‑Willi that support Phase III planning. Rhythm stressed it is well capitalized and does not need to raise funds in the near term, but cited access to endocrinologists and the need for multiple studies in Prader‑Willi as operational challenges. The company is also developing follow‑on programs (RM‑718, Bivamelagon) to strengthen the pipeline and long‑term competitive position. » More on de.investing.com
Rhythm Pharmaceuticals receives Japanese approval for Imcivree to treat acquired hypothalamic obesity

Japan’s Ministry of Health, Labour and Welfare has approved Imcivree (setmelanotid) from Rhythm Pharmaceuticals for the treatment of acquired hypothalamic obesity, the first approved therapy for this form in Japan. Rhythm estimates the patient population in Japan at 5,000–8,000 and plans to launch the product before the end of 2026, depending on pricing. The approval is based on the phase‑3 TRANSCEND study, which showed a placebo‑adjusted BMI reduction of 18.8%; Imcivree is already approved in the US and the EU. » More on de.investing.com
Rhythm Pharmaceuticals: US launch of IMCIVREE gains momentum

Rhythm reports that the US launch of IMCIVREE for acquired hypothalamic obesity is showing strong early demand, with more than 400 therapy requests in 14 weeks and prescriptions from over 300 physicians. About two-thirds of requests were approved by quarter-end; coverage policies account for roughly 25% of commercially insured and 35% of Medicaid beneficiaries. The company holds about $330 million in cash, sufficient for roughly 24 months, and does not see a near-term need for an equity raise. Rhythm is also advancing a pipeline of MC4R agonists, plans Phase III strategies for Prader-Willi before the end of 2025, and intends to further develop bivamelagon and other programs globally. » More on de.investing.com

Financials

In the last quarter, Rhythm Pharmaceuticals Inc had revenue of €62.43M and net profit of -€43.2M

(EUR)	June 2026	YoY
Revenue	62.43M	51.72%
Gross profit	54.61M	49.83%
Net profit	-43.2M	9.18%
EBITDA	-38.61M	13.48%

Fundamentals

Metric	Value
Market capitalization	€5.5B
Number of shares	68.85M
52-week high/low	€108.90 - €66.39
Dividends	No
Beta	2.01
P/E ratio	-28.84
PEG ratio	7.21
P/B ratio	28.31
P/S ratio	25.74

Company profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.